From care to cure: Demonstrating a model of clinical patient navigation for hepatitis C care and treatment in high-need patients

Clinical Infectious Diseases

Volumn 64, Issue 5, 2017, Pages 685-691

  Ford, Mary M ^a   Johnson, Nirah ^a   Desai, Payal ^a   Rude, Eric ^a   Laraque, Fabienne ^a  

^a NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

Author keywords

Access to care; Hepatitis c; Patient navigation; Sustained virologic response

Indexed keywords

ADULT; ARTICLE; CLINICAL OUTCOME; COUNSELING; FEMALE; HARM REDUCTION; HEALTH CARE NEED; HEALTH CARE ORGANIZATION; HEPATITIS C; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL CARE; MEDICATION COMPLIANCE; MENTAL HEALTH; PATIENT CARE; PRIORITY JOURNAL; REIMBURSEMENT; RISK ASSESSMENT; SOCIAL SUPPORT; SUBSTANCE USE; SUSTAINED VIROLOGIC RESPONSE;

EID: 85018179980     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw806     Document Type: Article

References (28)

1. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. Available at: http://www.cdc.gov/std/treatment/2010/hepc.htm. Accessed 15 April 2016.
2. Yehia BR, Schranz AJ, Umscheid CA, Lo Re V 3rd. The treatment cascade for chronic hepatitis C virus infection in the United States: A systematic review and meta-analysis. PLoS One 2014; 9:e101554.
3. Balter S, Stark JH, Kennedy J, Bornschlegel K, Konty K. Estimating the prevalence of hepatitis C infection in New York City using surveillance data. Epidemiol Infect 2014; 142:262-9.
4. Alter MJ, Hadler SC, Judson FN, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990; 264:2231-5.
5. Parmar P, Corsi DJ, Cooper C. Distribution of hepatitis C risk factors and HCV treatment outcomes among central Canadian aboriginal. Can J Gastroenterol Hepatol 2016; 2016:8987976.
6. Hilgenfeldt EG, Schlachterman A, Firpi RJ. Hepatitis C: treatment of difficult to treat patients. World J Hepatol 2015; 7:1953-63.
7. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: The best interferon-free combinations. Liver Int 2014; 34:69-78.
8. Gritsenko D, Hughes G. Ledipasvir/sofosbuvir (Harvoni): improving options for hepatitis C virus infection. P T 2015; 40:256-76.
9. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67:117-23.
10. Haley SJ, Kreek MJ. A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act. Am J Public Health 2015; 105:457-63.
11. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015; 163:215-23.
12. North CS, Hong BA, Adewuyi SA, et al. Hepatitis C treatment and SVR: The gap between clinical trials and real-world treatment aspirations. Gen Hosp Psychiatry 2013; 35:122-8.
13. Mugavero MJ, Amico KR, Horn T, Thompson MA. The state of engagement in HIV care in the United States: from cascade to continuum to control. Clin Infect Dis 2013; 57:1164-71.
14. Koester KA, Morewitz M, Pearson C, et al. Patient navigation facilitates medical and social services engagement among HIV-infected individuals leaving jail and returning to the community. AIDS Patient Care STDS 2014; 28:82-90.
15. Braun KL, Kagawa-Singer M, Holden AE, et al. Cancer patient navigator tasks across the cancer care continuum. J Health Care Poor Underserved 2012; 23:398-413.
16. Fiscella K, Whitley E, Hendren S, et al. Patient navigation for breast and colorectal cancer treatment: A randomized trial. Cancer Epidemiol Biomarkers Prev 2012; 21:1673-81.
17. Freeman HP. Patient navigation as a targeted intervention: for patients at high risk for delays in cancer care. Cancer 2015; 121:3930-2.
18. Trooskin SB, Poceta J, Towey CM, et al. Results from a geographically focused, community-based HCV screening, linkage-to-care and patient navigation program. J Gen Intern Med 2015; 30:950-7.
19. Ford M, Jordan A, Johnson N, et al. Check Hep C: A community-based approach to hepatitis C diagnosis and linkage to care in high-risk populations. J Public Health Manag Pract 2016. In press.
20. SAS Institute. SAS system for Windows. 9.1 ed. Cary, NC: SAS Institute, 2011.
21. Coyle C, Viner K, Hughes E, et al. Identification and linkage to care of HCVinfected persons in five health centers-Philadelphia, Pennsylvania, 2012-2014. MMWR Morb Mortal Wkly Rep 2015; 64:459-63.
22. Morano JP, Zelenev A, Lombard A, Marcus R, Gibson BA, Altice FL. Strategies for hepatitis C testing and linkage to care for vulnerable populations: point-of-care and standard HCV testing in a mobile medical clinic. J Community Health 2014; 39:922-34.
23. Sulkowski MS, Vargas HE, Di Bisceglie AM, et al; HCV-TARGET Study Group. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology 2016; 150:419-29.
24. Zoulim F, Liang TJ, Gerbes AL, et al. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut 2015; 64:1824-33.
25. Lo Re V 3rd, Gowda C, Urick PN, et al. Disparities in absolute denial of modern hepatitis C therapy by type of insurance. Clin Gastroenterol Hepatol 2016; 14:1035-43.
26. American Association for the Study of Liver Diseases/Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Available at: http://hcvguidelines.org/. Accessed 15 June 2016.
27. Razavi H, Elkhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013; 57:2164-70.
28. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009; 50:1750-5.